Edward

BACK THE TRUCK UP!

Climb Bio, Inc. (CLYM)'s Technical Outlook is Bright After Key Golden Cross
Zacks Equity Research September 03, 2025
CLYM Quick QuoteCLYM

Zack's Triangle IconBetter trading starts here.

Facebook Tweet LinkedIn Pinterest Email StockTwits
Hide Full Article
After reaching an important support level, Climb Bio, Inc. (CLYM Quick QuoteCLYM - Free Report) could be a good stock pick from a technical perspective. CLYM recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

There's a reason traders love a golden cross -- it's a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock's short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.

A successful golden cross event has three stages. It first begins when a stock's price on the decline bottoms out. Then, its shorter moving average crosses above its longer moving average, triggering a positive trend reversal. The third and final phase occurs when the stock maintains its upward momentum.

This kind of chart pattern is the opposite of a death cross, which is a technical event that suggests future bearish price movement.

Over the past four weeks, CLYM has gained 28.2%. The company currently sits at a #2 (Buy) on the Zacks Rank, also indicating that the stock could be poised for a breakout.

Once investors consider CLYM's positive earnings outlook for the current quarter, the bullish case only solidifies. No earnings estimate has gone lower in the past two months compared to 2 revisions higher, and the Zacks Consensus Estimate has increased as well.

Investors may want to watch CLYM for more gains in the near future given the company's key technical level and positive earnings estimate revisions.

506,000 Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Purchased by Boxer Capital Management LLC
Written by MarketBeat
Updated May 6, 2025
Black Diamond Therapeutics logo with Medical background
Boxer Capital Management LLC acquired a new stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 506,000 shares of the company's stock, valued at approximately $1,083,000. Boxer Capital Management LLC owned 0.89% of Black Diamond Therapeutics at the end of the most recent reporting period.